Epidemiology and risk factors

Henry T. Lynch, P. Watson, J. F. Lynch

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

HBC is common, accounting for approximately 9% of the total breast cancer burden. Given 142,000 cases of breast cancer expected to occur in 1989, this would represent 12,780 cases of HBC patients. Soberingly, each patient represents a family with a variable number of inordinately high risk patients. HBC's natural history is distinctive and enables the identification of at risk patients who can benefit from highly targeted surveillance/management strategies. High priority must be given to development of biomarkers that will one day be found to have acceptable sensitivity and specificity to genotype status. Thus, we would then be able to tell which of the first-degree relatives of affected members have inherited the deleterious gene. This would result in a significant saving of time and money that would otherwise be expended through intensive surveillance strategies. We need cost-benefit research to induce third party carriers to defray expenses for surveillance. Finally, priority attention must be given to biomolecular research for identification of markers of acceptable sensitivity and specificity to the cancer-prone genotype. Eventual cloning of the deleterious gene(s) could lead to knowledge about its chemical and physiologic products, thereby enabling anticancer pharmacologic research. The reward could then be improved control and even prevention of breast cancer, and possibly of the associated cancers in heterogenous forms of this disease.

Original languageEnglish
Pages (from-to)750-760
Number of pages11
JournalClinical Obstetrics and Gynecology
Volume32
Issue number4
DOIs
StatePublished - 1989

Fingerprint

Epidemiology
Breast Neoplasms
Genotype
Research
Sensitivity and Specificity
Natural History
Reward
Genes
Cost-Benefit Analysis
Organism Cloning
Neoplasms
Biomarkers

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Epidemiology and risk factors. / Lynch, Henry T.; Watson, P.; Lynch, J. F.

In: Clinical Obstetrics and Gynecology, Vol. 32, No. 4, 1989, p. 750-760.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Watson, P. ; Lynch, J. F. / Epidemiology and risk factors. In: Clinical Obstetrics and Gynecology. 1989 ; Vol. 32, No. 4. pp. 750-760.
@article{bf2732d421604e03a1696e77341df3ee,
title = "Epidemiology and risk factors",
abstract = "HBC is common, accounting for approximately 9{\%} of the total breast cancer burden. Given 142,000 cases of breast cancer expected to occur in 1989, this would represent 12,780 cases of HBC patients. Soberingly, each patient represents a family with a variable number of inordinately high risk patients. HBC's natural history is distinctive and enables the identification of at risk patients who can benefit from highly targeted surveillance/management strategies. High priority must be given to development of biomarkers that will one day be found to have acceptable sensitivity and specificity to genotype status. Thus, we would then be able to tell which of the first-degree relatives of affected members have inherited the deleterious gene. This would result in a significant saving of time and money that would otherwise be expended through intensive surveillance strategies. We need cost-benefit research to induce third party carriers to defray expenses for surveillance. Finally, priority attention must be given to biomolecular research for identification of markers of acceptable sensitivity and specificity to the cancer-prone genotype. Eventual cloning of the deleterious gene(s) could lead to knowledge about its chemical and physiologic products, thereby enabling anticancer pharmacologic research. The reward could then be improved control and even prevention of breast cancer, and possibly of the associated cancers in heterogenous forms of this disease.",
author = "Lynch, {Henry T.} and P. Watson and Lynch, {J. F.}",
year = "1989",
doi = "10.1097/00003081-198912000-00018",
language = "English",
volume = "32",
pages = "750--760",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Epidemiology and risk factors

AU - Lynch, Henry T.

AU - Watson, P.

AU - Lynch, J. F.

PY - 1989

Y1 - 1989

N2 - HBC is common, accounting for approximately 9% of the total breast cancer burden. Given 142,000 cases of breast cancer expected to occur in 1989, this would represent 12,780 cases of HBC patients. Soberingly, each patient represents a family with a variable number of inordinately high risk patients. HBC's natural history is distinctive and enables the identification of at risk patients who can benefit from highly targeted surveillance/management strategies. High priority must be given to development of biomarkers that will one day be found to have acceptable sensitivity and specificity to genotype status. Thus, we would then be able to tell which of the first-degree relatives of affected members have inherited the deleterious gene. This would result in a significant saving of time and money that would otherwise be expended through intensive surveillance strategies. We need cost-benefit research to induce third party carriers to defray expenses for surveillance. Finally, priority attention must be given to biomolecular research for identification of markers of acceptable sensitivity and specificity to the cancer-prone genotype. Eventual cloning of the deleterious gene(s) could lead to knowledge about its chemical and physiologic products, thereby enabling anticancer pharmacologic research. The reward could then be improved control and even prevention of breast cancer, and possibly of the associated cancers in heterogenous forms of this disease.

AB - HBC is common, accounting for approximately 9% of the total breast cancer burden. Given 142,000 cases of breast cancer expected to occur in 1989, this would represent 12,780 cases of HBC patients. Soberingly, each patient represents a family with a variable number of inordinately high risk patients. HBC's natural history is distinctive and enables the identification of at risk patients who can benefit from highly targeted surveillance/management strategies. High priority must be given to development of biomarkers that will one day be found to have acceptable sensitivity and specificity to genotype status. Thus, we would then be able to tell which of the first-degree relatives of affected members have inherited the deleterious gene. This would result in a significant saving of time and money that would otherwise be expended through intensive surveillance strategies. We need cost-benefit research to induce third party carriers to defray expenses for surveillance. Finally, priority attention must be given to biomolecular research for identification of markers of acceptable sensitivity and specificity to the cancer-prone genotype. Eventual cloning of the deleterious gene(s) could lead to knowledge about its chemical and physiologic products, thereby enabling anticancer pharmacologic research. The reward could then be improved control and even prevention of breast cancer, and possibly of the associated cancers in heterogenous forms of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0024786823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024786823&partnerID=8YFLogxK

U2 - 10.1097/00003081-198912000-00018

DO - 10.1097/00003081-198912000-00018

M3 - Article

VL - 32

SP - 750

EP - 760

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 4

ER -